[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342900-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342900-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","characterization-of-met-alterations-in-37-gastroesophageal-cancer-cell-lines-for-met-targeted-therapy","Characterization of MET Alterations in 37 Gastroesophageal Cancer Cell Lines for MET-Targeted Therapy","","Capmatinib and savolitinib, selective MET inhibitors, were evaluated for their effects on MET-amplified gastric cancer (GC) cells. After screening 37 GC cell lines, MET-positive lines with copy number variation >10 were identified. Capmatinib or savolitinib cytotoxic responses were measured using CCK-8 and clonogenic assays, while Western blotting assessed MET pathway suppression. In vivo, savolitinib showed anti-tumor efficacy in an MKN-45 xenograft model, and combined trastuzumab plus capmatinib enhanced AKT/ERK inhibition in HER2- and MET-positive cells.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/characterization-of-met-alterations-in-37-gastroesophageal-cancer-cell-lines-for-met-targeted-therapy/342900/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/characterization-of-met-alterations-in-37-gastroesophageal-cancer-cell-lines-for-met-targeted-therapy/342900.png","ImageObject",300,407,{"name":42,"@type":43},"Violet","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How were MET-positive gastric cancer cell lines identified in the study?","Question",{"text":63,"@type":64},"The study screened 37 gastric cancer cell lines and selected MET-positive lines showing copy number variation greater than 10.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What experimental methods were used to assess the drug effects in vitro?",{"text":68,"@type":64},"Cytotoxicity was evaluated with CCK-8 and clonogenic cell survival assays, and Western blotting was used to examine changes in MET signaling and downstream pathways.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the in vivo experiments show for savolitinib?",{"text":72,"@type":64},"Savolitinib produced dose-dependent anti-tumor effects and reduced colony formation in a soft-agar context, and it suppressed growth in an MKN-45 gastric cancer xenograft model.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342900,1791316993,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},4398048950312,"https://ap-avatar.wpscdn.com/avatar/400002538284de19e3c?_k=1778320343897328908","Article  \nCharacterization of MET Alterations in 37 Gastroesophageal Cancer Cell Lines for MET-Targeted Therapy  \nJin-Soo Kim 1,*, Mi Young Kim 1 and Sungyoul Hong 2  \nCitation: Kim, J.-S.; Kim, M.Y.; Hong, S. Characterization of MET Alterations in 37 Gastroesophageal Cancer Cell Lines for MET-Targeted Therapy. Int. J. Mol. Sci. 2024, 25, 5975 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms25115975  \nAcademic Editor: Marlena Brzozowa-Zasada  \nReceived: 16 May 2024  \nRevised: 26 May 2024  \nAccepted: 28 May 2024  \nPublished: 29 May 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul 07061, Republic of Korea; [moung9805@naver.com](moung9805@naver.com)  \n2 College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea; [sungyoul@snu.ac.kr](sungyoul@snu.ac.kr)  \n* Correspondence: [gistmd74@snu.ac.kr](gistmd74@snu.ac.kr); Tel.: +82-2-870-3202  \nAbstract: Capmatinib and savolitinib, selective MET inhibitors, are widely used to treat various MET-positive cancers. In this study, we aimed to determine the effects of these inhibitors on MET-amplified gastric cancer (GC) cells. Methods: After screening 37 GC cell lines, the following cell lines were found to be MET-positive with copy number variation >10: SNU-620, ESO51, MKN-45, SNU-5, and OE33 cell lines. Next, we assessed the cytotoxic response of these cell lines to capmatinib or savolitinib alone using cell counting kit-8 and clonogenic cell survival assays. Western blotting was performed to assess the effects of capmatinib and savolitinib on the MET signaling pathway. Xenograft studies were performed to evaluate the in vivo therapeutic efficacy of savolitinibin MKN-45 cells. Savolitinib and capmatinib exerted anti-proliferative effects on MET-amplified GC cell lines in a dose-dependent manner. Savolitinib inhibited the phosphorylation of MET and downstream signaling pathways, such as the protein kinase B (AKT) and extracellular signal-regulated kinase (ERK) pathways, in MET-amplified GC cells. Additionally, savolitinib significantly decreased the number of colonies formed on the soft agar and exerted dose-dependent anti-tumor effects in an MKN-45 GC cell xenograft model. Furthermore, a combination of trastuzumab and capmatinib exhibited enhanced inhibition of AKT and ERK activation in human epidermal growth factor receptor-2 (HER2)-and MET-positive OE33 cells. Targeting MET with savolitinib and capmatinib efficiently suppressed the growth of MET-amplified GC cells. Moreover, these MET inhibitors exerted synergistic effects with trastuzumab on HER2-and MET-amplified GC cells.  \nKeywords: gastric cancer; proto-oncogene protein c-met; tyrosine kinase inhibitors; cell line; tumor  \n1. Introduction  \nGastric cancer (GC) is among the most common cancers worldwide, with more than one million new cases reported annually [1] and figures suggesting it is the 3rd most deadly cancer, with an estimated 783,000 deaths in 2018 [2] . During the last few decades, the efficacy of chemotherapy for GC has only advanced modestly, and targeted therapies have shown few successes. Many human epidermal growth factor receptor-2 (HER2)-targeting agents, such as lapatinib, pertuzumab, and T-DM1, have been tested; however, to date, only trastuzumab (Tmab) has been approved for HER2-positive GC treatment [3] . To dissect the genomic pathophysiology of GC in greater depth, The Cancer Genome Atlas (TCGA) reported GC subgroups and has shown that the disease can be categorized into four genomic subtypes and suggested several candidates for targeted therapy [4] . F","cbCaitMgeLLnG4xL","https://ap.wps.com/l/cbCaitMgeLLnG4xL","pdf",3106496,13,"English","# Abstract\n# Introduction","[{\"question\":\"How were MET-positive gastric cancer cell lines identified in the study?\",\"answer\":\"The study screened 37 gastric cancer cell lines and selected MET-positive lines showing copy number variation greater than 10.\"},{\"question\":\"What experimental methods were used to assess the drug effects in vitro?\",\"answer\":\"Cytotoxicity was evaluated with CCK-8 and clonogenic cell survival assays, and Western blotting was used to examine changes in MET signaling and downstream pathways.\"},{\"question\":\"What did the in vivo experiments show for savolitinib?\",\"answer\":\"Savolitinib produced dose-dependent anti-tumor effects and reduced colony formation in a soft-agar context, and it suppressed growth in an MKN-45 gastric cancer xenograft model.\"}]","Characterization of MET Alterations in 37 Gastroesophageal Cancer Cell Lines for MET-Targeted Therapy | PDF",1790048729,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/422a5fbe6db14d50bdc5a82b656bb374.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d80aae32535f8020959a8947054cddc1.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8abd5705fd984aac83c4075f6f0af40e.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2e49f5834a83c29f1099c638e5f5d02b.webp",980,1385]